Financial Performance - Total revenue for 2025 reached 767.75 million CNY, a year-on-year increase of 3.26%[3] - Net profit attributable to shareholders decreased by 23.55% to 78.70 million CNY[3] - Net profit excluding non-recurring gains and losses fell by 34.48% to 58.95 million CNY[3] - Basic earnings per share decreased by 22.73% to 0.51 CNY[3] - The weighted average return on equity decreased by 1.32 percentage points to 3.70%[3] Assets and Equity - Total assets increased by 11.64% to 3,268.63 million CNY[3] - Shareholders' equity attributable to the parent company rose by 1.54% to 2,070.10 million CNY[3] Operational Factors - The decline in net profit was primarily due to increased R&D expenses and depreciation costs[6] - The company continues to focus on technological innovation and improving operational efficiency[5] Report Accuracy - There are no significant uncertainties affecting the accuracy of the performance report[7]

Financial Performance - In 2025, the company achieved total operating revenue of 1,017.93 million yuan, an increase of 43.23% compared to the same period last year[5] - The operating profit for 2025 was -412.26 million yuan, a reduction in loss of 46.97% year-on-year[7] - The net profit attributable to the parent company was -336.66 million yuan, a reduction in loss of 48.12% compared to the previous year[9] - The basic earnings per share for 2025 was -0.85 yuan, a reduction in loss of 47.85% year-on-year[9] Assets and Returns - The company's total assets at the end of 2025 were 4,671.22 million yuan, a decrease of 5.24% from the beginning of the period[7] - The weighted average return on net assets was -22.05%, an increase of 10.58 percentage points compared to the previous year[10] Revenue Drivers - The increase in revenue was primarily driven by higher sales volumes of photovoltaic cells and equipment[9] Future Plans - The company plans to continue increasing investment in product research and development to maintain its leading position in the industry[8] Caution for Investors - Investors are advised to be cautious as the financial data is preliminary and unaudited, with final figures to be disclosed in the official annual report[11] Impairment Provisions - The company reported a decrease in net profit due to prior asset impairment provisions related to 2GW PERC silicon wafers and cells[9]

Financial Performance - The company achieved total operating revenue of RMB 67,531.94 million, representing a year-on-year increase of 8.68%[4] - Operating profit was RMB -1,216.45 million, and total profit was RMB -278.24 million, both showing significant declines compared to the previous year[5] - Net profit attributable to shareholders of the parent company was RMB 1,269.42 million, an increase of 33.77% year-on-year[4] - The net profit attributable to shareholders of the parent company, excluding non-recurring gains and losses, was RMB -6,591.12 million, indicating a worsening situation compared to the previous year[5] - Basic earnings per share increased to RMB 0.08, up 33.33% from RMB 0.06 in the previous year[4] Assets and Equity - Total assets at the end of the reporting period were RMB 261,640.07 million, a 1.46% increase from the beginning of the period[5] - Shareholders' equity attributable to the parent company rose to RMB 173,344.49 million, reflecting a 2.13% increase[5] Operational Challenges and Strategy - The decline in operating profit and total profit was primarily due to increased operating costs from product expansion and enhanced employee compensation[5] - The company plans to continue its long-term development strategy by expanding product offerings and strengthening its talent pool[5] Financial Data Status - The financial data presented is preliminary and subject to adjustments pending the completion of audits and evaluations[6]

Financial Performance - Total operating revenue for 2025 reached RMB 523,726.28 million, a year-on-year increase of 13.55%[3] - Net profit attributable to shareholders of the parent company was RMB 84,046.01 million, up 4.95% compared to the previous year[3] - Net profit attributable to shareholders of the parent company after deducting non-recurring gains and losses decreased by 3.42% to RMB 68,834.53 million[3] - Basic earnings per share increased by 4.96% to RMB 1.2937[3] Assets and Equity - Total assets at the end of the reporting period were RMB 1,507,361.29 million, reflecting a growth of 10.76% from the beginning of the period[5] - Equity attributable to shareholders of the parent company rose by 6.61% to RMB 712,556.29 million[5] - Net asset value per share attributable to shareholders of the parent company increased by 6.61% to RMB 10.97[5] Market and Production Strategy - The company focused on expanding domestic and international markets amid intensified competition[5] - The production capacity and shipment volume of high-end titanium alloys, superconducting products, and high-performance high-temperature alloys increased during the reporting period[5] - The company is accelerating the construction of intelligent production lines to ensure product quality and improve cost management[5]

Financial Performance - The company achieved total operating revenue of RMB 434,281,777.57, representing a year-on-year increase of 12.06%[6] - Net profit attributable to the parent company reached RMB 35,271,855.34, a significant increase of 120.44% compared to the previous year[6] - The net profit attributable to the parent company after deducting non-recurring gains and losses was RMB 34,231,391.70, reflecting a growth of 231.42% year-on-year[6] - Operating profit increased by 76.48% to RMB 39,010,897.34, driven by steady growth in the smart factory equipment business and the development of computing server business[7] - Basic earnings per share rose to RMB 0.57, marking a 119.23% increase compared to the previous year[6] Assets and Equity - Total assets at the end of the reporting period amounted to RMB 1,065,597,527.65, up 31.95% from the previous year[6] - Equity attributable to the parent company was RMB 485,005,847.00, an increase of 4.51% year-on-year[6] - The increase in total assets was primarily due to business growth leading to higher inventory and accounts receivable, as well as increased long-term equity investments[7] Investment and Risk Management - The company’s long-term equity investment income contributed significantly to overall profitability, supporting performance growth[6] - The company emphasizes the importance of monitoring investment risks as the financial data is preliminary and unaudited[9]

| 证券代码：688135 | 证券简称：利扬芯片 | 公告编号：2026-021 | | --- | --- | --- | | 转债代码：118048 | 转债简称：利扬转债 | | 广东利扬芯片测试股份有限公司 2025 年度业绩快报公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 本公告所载2025年度主要财务数据为初步核算数据，未经会计师事务所审计， 具体数据以广东利扬芯片测试股份有限公司（以下简称"公司"）2025年年度的 定期报告为准，敬请投资者注意投资风险。 一、2025 年度主要财务数据和指标 单位：人民币万元 | 项目 | 本报告期 | 上年同期 | 增减变动幅度（％） | | --- | --- | --- | --- | | 营业总收入 | 61,839.44 | 48,812.56 | 26.69 | | 营业利润 | -913.88 | -5,581.62 | 不适用 | | 利润总额 | -1,087.86 | -5,599.17 | 不适用 | | 归属于母公司所有者的净利润 | -91 ...

Financial Performance - Total revenue for 2025 was RMB 51,457.25 million, a decrease of 26.41% compared to the previous year[4] - Net profit attributable to shareholders of the parent company was -RMB 7,998.80 million, down 276.97% year-on-year[4] - The weighted average return on equity decreased by 13.75 percentage points to -8.94%[4] - Basic earnings per share fell to -RMB 0.67, a decline of 276.32% compared to the previous year[4] Asset Management - The company recorded a total asset increase of 5.48%, reaching RMB 190,812.31 million at the end of the reporting period[7] - Equity attributable to shareholders of the parent company decreased by 10.76% to RMB 84,393.94 million[7] - The company recognized an asset impairment provision of approximately RMB 11,213.00 million, significantly impacting current performance[12] Strategic Initiatives - The company plans to strategically reduce its energy storage business due to ongoing losses and market challenges[10] - The company has initiated the establishment of new overseas subsidiaries to support market expansion[8] Research and Development - Research and development expenses increased compared to the previous year, supporting ongoing new technology and product development[8]

Financial Performance - In 2025, the company achieved total operating revenue of RMB 950.29 million, an increase of 0.89% compared to the previous year[4] - The net profit attributable to shareholders of the listed company reached RMB 415.60 million, reflecting an increase of 8.70% year-on-year[4] - Basic earnings per share increased to RMB 0.90, representing a growth of 9.76% from the previous year[4] - The company reported a net profit after deducting non-recurring gains and losses of RMB 350.28 million, an increase of 12.31% year-on-year[4] - The weighted average return on net assets was 10.16%, an increase of 0.27 percentage points compared to the previous year[4] Assets and Equity - Total assets at the end of the reporting period amounted to RMB 4.79 billion, a growth of 6.55% from the beginning of the year[5] - Shareholders' equity attributable to the listed company was RMB 4.24 billion, up 7.64% compared to the start of the year[5] Research and Development - The company has intensified its R&D efforts and accelerated new product development to enhance market competitiveness[6] Financial Data Integrity - There were no financial data items with a change of 30% or more during the reporting period[6] - The company emphasizes the importance of investor awareness regarding potential risks due to preliminary financial data not yet audited[8]

Financial Performance - Total revenue for 2025 reached RMB 249,842.03 million, a year-on-year increase of 28.23% compared to RMB 194,831.73 million in the previous year[3] - The net loss attributable to shareholders of the parent company was RMB 87,438.94 million, a significant reduction from RMB 128,092.64 million in the previous year[3] - The weighted average return on equity improved to -14.70%, an increase of 5.01 percentage points from -19.71% in the previous year[3] - The company expects a net profit attributable to shareholders of the parent company, excluding stock payment impacts, to be around RMB -79,798.56 million, a reduction in loss of approximately 37.70% year-on-year[5] Product Performance - The core product, Toripalimab injection (brand name: Tuoyi®), saw a sales revenue increase of approximately 37.72% in the domestic market[6] - Toripalimab has been approved for 12 indications in mainland China, all included in the national medical insurance catalog[6] Assets and Investments - The total assets at the end of the reporting period were RMB 1,238,904.33 million, reflecting a 14.91% increase from RMB 1,078,196.04 million at the beginning of the period[3] Research and Development - The company is advancing multiple innovative drugs in clinical trials, including JS207, which is currently in Phase II trials[7] Strategic Focus - The company is focused on enhancing commercialization capabilities while controlling costs, leading to a significant narrowing of net losses compared to the previous year[7] - The company has expanded its global commercialization network, with Toripalimab approved in over 40 countries and regions[6]

Financial Performance - Total operating revenue for 2025 was CNY 315.34 million, a decrease of 9.15% compared to CNY 347.09 million in the previous year[5] - Operating profit fell to CNY 7.77 million, down 48.58% from CNY 15.12 million year-on-year[5] - Total profit decreased by 49.87% to CNY 7.49 million from CNY 14.94 million in the previous year[5] - Net profit attributable to shareholders was CNY 7.81 million, a decline of 43.00% compared to CNY 13.70 million in the previous year[5] - Net profit after deducting non-recurring gains and losses dropped by 79.00% to CNY 1.91 million from CNY 9.10 million year-on-year[5] - Basic earnings per share decreased by 40.00% to CNY 0.06 from CNY 0.10 in the previous year[5] Assets and Equity - Total assets at the end of the reporting period were CNY 695.71 million, a decrease of 2.37% from CNY 712.61 million at the beginning of the period[6] - Shareholders' equity attributable to the company increased by 0.21% to CNY 550.78 million from CNY 549.64 million at the beginning of the period[6] Operational Challenges - The company faced operational pressure primarily due to a decline in the automotive mold parts business, which was affected by increased procurement costs and intensified market competition[7] - Despite growth in the medical device and automation parts segments, the overall performance was negatively impacted by the decline in the automotive mold parts business[7]